Reference is made to the stock exchange notice
published on 22 June 2018 regarding a private placement with gross
proceeds of approximately NOK 123.2 million (the "Private Placement") and the stock exchange notice
published on 19 June 2018 regarding a contemplated repair issue
following the Private Placement (the "Subsequent
Offering"). The general meeting of Hofseth BioCare ASA
("HBC" or the "Company")
resolved the share capital increases related to the Private
Placement and the Subsequent Offering on 16 July 2018.
The Financial Supervisory Authority of Norway has
on 23 August 2018 approved a prospectus prepared by the Company
(the "Prospectus") in connection with the
listing of the new shares issued in the Private Placement and the
offering and listing of offer shares in the Subsequent
Offering.
The shares issued in the Private Placement,
currently registered on a separate ISIN, will as a consequence be
transferred to the ordinary ISIN of the Company as of today.
The Prospectus is available at the website of
Sparebank 1 Markets (the "Manager"),
www.sb1markets.no, and the website of the Company,
www.hofsethbiocare.com.
The Subsequent Offering comprises an issuance of
up to 8,888,889 new shares in the Company (the "Offer Shares"), each with a par value of NOK 1, and at
a subscription price of NOK 2.25 per Offer Share.
The Subsequent Offering will be directed towards
Eligible Shareholders, being the Company's shareholders as of 18
June 2018, as registered in the VPS on 20 June 2018, except (i)
shareholders who participated in the Private Placement, and (ii)
shareholders who are resident in a jurisdiction where such offering
would be unlawful or would require any filing, registration or
similar action (other than a prospectus in Norway).
The Eligible Shareholders will be granted 0.1616
non-tradable subscription rights ("Subscription
Rights") per share held as of 18 June 2018, as registered in
the VPS on 20 June 2018. Each Subscription Right will give a
preferential right to subscribe for and be allocated one Offer
Share. The number of Subscription Rights issued to each Eligible
Shareholder will be rounded down to the nearest whole number of
Subscription Rights. Oversubscription will be allowed. Subscription
without Subscription Rights will not be allowed.
The subscription period in the Subsequent Offering
commences on 27 August 2018 at 09.00 hours and expires on 10
September 2018 at 16.30 hours.
Further information about the Subsequent Offering
is available in the Prospectus.
For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Mob: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value
ingredients and finished products for humans and pets. The company
is founded on the core values of sustainability, traceability and
optimal utilization of natural resources. Through an innovative
hydrolysis technology, HBC is able to preserve the quality of
salmon oil, proteins and calcium, prepared of fresh salmon
off-cuts. HBC's objective is to contribute to the efficient use of
marine resources and deliver quality products for ingredients and
finished consumer products in the nutrition market.
Hofseth BioCare's headquarters are located in Ålesund, Norway with
branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo
Stock Exchange Axess list with ticker "HBC". More information about
Hofseth BioCare at www.hofsethbiocare.com and
www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.